Gujarat Themis Acquires Sanofi's TB/Anti-Infective Portfolio for €158 Million
Gujarat Themis Biosyn Limited is acquiring Sanofi's Anti-Tuberculosis and Anti-Infectives portfolio for €158 million. This asset deal includes brands and marketing authorizations, expanding its reach to 59 countries. The company also announced its intent to acquire MicroBiopharm Japan for JPY 9.5 billion.
The acquisition of a significant product portfolio from Sanofi, coupled with the planned acquisition of a Japanese company, represents a major strategic shift for Gujarat Themis, substantially increasing its market presence, revenue potential, and diversification into higher-value segments of the pharmaceutical industry.
The acquisition of Sanofi's established product portfolio and the planned acquisition of MicroBiopharm Japan are strategic moves that are expected to significantly expand the company's geographical reach, product offerings, and capabilities, positioning it for future growth.
Gujarat Themis Biosyn Limited has announced its strategic acquisition of Sanofi's select product portfolio, focusing on Anti-Tuberculosis and Anti-Infectives. The deal, valued at €158 million (approximately ₹1,395 crore), includes marketing authorizations, regulatory documentation, relevant contracts, and inventory, but excludes manufacturing facilities and employees.
This acquisition will grant Gujarat Themis immediate geographical expansion, with reach to 59 countries, strengthening its presence in Europe and the Middle East & Africa. The acquired portfolio generated €62 million in net sales in CY25, with significant contributions from the Middle East & Africa (34.24%) and Europe (27.23%). Key molecules in the portfolio include Rifampicin, Rifapentine, and Levofloxacin.
The strategic rationale behind this asset-light acquisition includes forward integration to complement existing fermentation strengths with API and finished formulations, creating an integrated value chain. It also offers headroom for margin expansion through API integration and cost optimization, leveraging the established brand equity of Sanofi-originated products which are recognized as essential medicines by global health organizations. The company aims to move up the pharma value chain from APIs to specialty small molecules, biologics, and gene therapy, accelerating its transition towards a globally integrated CDMO.
In a separate development, Gujarat Themis is also in the process of acquiring MicroBiopharm Japan for JPY 9.5 billion (INR 561.82 crore), subject to regulatory approvals. This acquisition aims to enhance fermentation and precision biotech capabilities, expand the product portfolio to include immunosuppressants and oncology APIs, and build a CDMO platform with entry into advanced biologics and gene therapy.
What to do with a filing like this
Gujarat Themis Biosyn Limited filed this with the NSE as a statutory disclosure, categorised under acquisition. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gujarat Themis Biosyn Limited. Read the original for the full detail.